CKLF1 in cardiovascular and cerebrovascular diseases
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112718 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Chen Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: ery_chenc@lzu.edu.cn. Hauptthemen laut MEDLINE: MARVEL Domain-Containing Proteins, Cardiovascular Diseases, Cerebrovascular Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 104 Literaturangaben. Gefördert von: Lanzhou City Science and Technology Bureau, National Natural Science Foundation of China, Chinese Pharmaceutical Association.
Abstract (Originalsprache)
Chemokine like factor 1 (CKLF1) is a novel atypical chemokine, playing a crucial role in cardiovascular and cerebrovascular diseases (CCVDs) demonstrated by a growing body of works. In cardiovascular diseases including atherosclerosis and myocardial infarction, meanwhile in cerebrovascular diseases such as ischemic stroke and hemorrhagic stroke, the expression levels of CKLF1 change markedly, which triggers downstream signaling pathways by binding with its functional receptors, and then exerts multiple effects to participate in the occurrence and development of these CCVDs. The functional roles of CKLF1 are dynamic and CKLF1 may act as a double-edged sword. The CCVDs-promoting role is related to recruiting inflammatory cells, enhancing the proliferation of vascular smooth muscle cells and endothelial cells, while the CCVDs-suppressing role may correlate with migration of nerve cells and promotion of hematopoietic stem cell proliferation which contributes to disease recovery. Based on this, the paper intends to review expression shifts, potential roles, and molecular mechanisms of CKLF1 in CCVDs, and the current status of CKLF1 targeted therapeutic strategies is also included. We hope this review may provide a valuable reference for using CKLF1 as a diagnostic and prognostic biomarker for CCVDs or developing novel treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: ery_chenc@lzu.edu.cn.
- Hunan University of Traditional Chinese Medicine, Changsha 410208, China.
- Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou 730000, China.
Förderung
- Lanzhou City Science and Technology Bureau
- National Natural Science Foundation of China
- Chinese Pharmaceutical Association
- Gansu Province Science and Technology Department
- Lanzhou University First Affiliated Hospital
Zitieren
APA
Chen, C., Ai, Q., Tian, H., & Wei, Y. (2024). CKLF1 in cardiovascular and cerebrovascular diseases. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112718
Vancouver
Chen C, Ai Q, Tian H, Wei Y. CKLF1 in cardiovascular and cerebrovascular diseases. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112718
BibTeX
@article{Chen2024,
author = {Chen, Chen and Ai, Qidi and Tian, Haiyan and Wei, Yuhui},
title = {CKLF1 in cardiovascular and cerebrovascular diseases},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112718}
}
EUVIMED